Neladenoson bialanate

Summary

Neladenoson bialanate is an investigational oral pro‑drug that delivers a partial agonist of the adenosine A1 receptor. It has been developed to treat chronic heart failure, both with reduced (HFrEF) and preserved (HFpEF) ejection fraction, by exploiting the cardioprotective actions of adenosine while aiming to avoid the bradycardia and AV‑block seen with full agonists.

Mechanism of Action

Neladenoson bialanate is converted in the body to neladenoson, a selective partial agonist at the G‑protein‑coupled adenosine A1 receptor. Partial activation reduces adenylate cyclase activity, modulates protein kinase C, opens ATP‑sensitive potassium channels, and improves mitochondrial function and SERCA2a activity. These downstream effects are thought to limit ischemic injury, attenuate arrhythmogenesis, and promote favourable cardiac remodeling without markedly lowering heart rate or blood pressure.

What the Research Shows

Early pilot studies in HFrEF patients (single‑dose 30 mg and 7‑day 10‑20 mg regimens) showed that oral neladenoson bialanate was well tolerated, with no second‑ or third‑degree AV block, no heart‑rate or blood‑pressure changes, and only modest, non‑significant changes in left‑ventricular ejection fraction. A phase 2b dose‑finding trial (PANTHEON, 462 HFrEF patients) tested once‑daily doses of 5‑40 mg for 20 weeks and found no dose‑related improvement in LVEF, NT‑proBNP, ventricular volumes, troponin, mortality, or hospitalisations. A parallel phase 2b trial in HFpEF (305 patients) measured 6‑minute walk distance and similarly failed to demonstrate a clinically meaningful dose‑response. Across the larger trials, a dose‑dependent decline in renal function (creatinine, cystatin C, eGFR) was observed, while serious adverse events were comparable to placebo.

Reported Benefits

Preclinical models suggest partial A1‑receptor activation can protect myocardium from ischemic injury, improve mitochondrial efficiency, and enhance SERCA2a‑mediated calcium handling. In small pilot studies, neladenoson bialanate was safe, showing no AV‑block or overt haemodynamic effects, indicating a potentially favourable safety profile compared with full A1 agonists.

Limitations of the Evidence

Phase 2b trials have not demonstrated efficacy on cardiac structure, biomarkers, exercise capacity, or clinical outcomes in either HFrEF or HFpEF. The optimal therapeutic dose remains undefined, and a clear dose‑related renal function decline raises safety concerns. Evidence is limited to short‑term studies; long‑term effects are unknown, and the compound remains investigational with no regulatory approval.

Safety Considerations

Early pilot data reported no second‑ or third‑degree AV block, no bradyarrhythmias, and no significant changes in heart rate or blood pressure after single or short‑term dosing. In larger phase 2b studies, adverse events were similar to placebo, but a dose‑dependent increase in serum creatinine and cystatin C and a decrease in estimated glomerular filtration rate were noted, suggesting potential renal toxicity at higher doses. Caution is advised pending further safety evaluation.

How It Is Administered

Neladenoson bialanate is administered orally as a pro‑drug formulation designed to improve solubility and systemic exposure. Clinical trials have used once‑daily dosing ranging from 5 mg to 40 mg. No specific formulation details are provided beyond its oral route.

Routes of Administration

Goals & Uses

• Chronic heart failure with reduced ejection fraction (HFrEF)CardiovascularModerate
• CardioprotectionCardiovascularLow
• Heart rate reductionCardiovascularModerate
• Chronic heart failureCardiovascularModerate
• Heart failure with preserved ejection fraction (HFpEF)CardiovascularLow

Contraindications

• Second‑ or third‑degree AV blockCardiac ConductionHigh
• Severe bradycardiaCardiacHigh
• Known hypersensitivity to neladenoson or excipientsAllergyHigh
• Second or third degree AV blockCardiac ConductionHigh

Adverse Effects

• HypotensionCardiovascularCommonLow blood pressure
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• AV conduction prolongationCardiovascularUncommon
• DizzinessNeurologicUncommonFeeling faint, lightheaded, or unsteady
• BradycardiaCardiovascularCommon

Drug Interactions

• Calcium channel blockers (non-dihydropyridine)Moderate
• Beta‑blockersModerate
• Beta-blockersModerate
• DigoxinModerate
• Methylxanthines (e.g., theophylline, caffeine)Moderate

Population Constraints

• PregnancyReproductive SafetyRelative
• Severe renal impairmentOrgan ImpairmentRelative
• Pediatric patientsAgeRelative
• Severe hepatic impairmentOrgan ImpairmentRelative
• Severe renal impairment (eGFR <30 mL/min)RenalRelative

Regulatory Status

• European UnionInvestigationalNo marketing authorization granted.
• United StatesInvestigationalPhase II completed; development discontinued.
• United KingdomInvestigationalNo approval; investigational use only in clinical trial context.

Completed Phase II trials in heart failure; development halted; never received marketing authorization.

Evidence & Sources

• Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure
  Journal ArticleModerateVoors AA, et al.2017-01-01T00:00:00.000000Z
• Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A(1) Receptor Agonist for the Chronic Treatment of Heart Diseases
  Journal ArticleLowMeibom D, et al.2017-01-01T00:00:00.000000Z
• Partial Adenosine A1 Agonist in Heart Failure
  Journal ArticleModerateDinh W, et al.2017-01-01T00:00:00.000000Z
• Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction
  Journal ArticleModerateVoors AA, et al.2018-01-01T00:00:00.000000Z
• Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial
  Journal ArticleModerateVoors AA, et al.2019-01-01T00:00:00.000000Z
• Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial
  Journal ArticleModerateShah SJ, et al.2019-01-01T00:00:00.000000Z

Frequently Asked Questions